Mark N Lampert - Net Worth and Insider Trading
Mark N Lampert Net Worth
The estimated net worth of Mark N Lampert is at least $45 Million dollars as of 2025-04-28. Mark N Lampert is the Director, 10% Owner of Arena Pharmaceuticals Inc and owns about 452,021 shares of Arena Pharmaceuticals Inc (ARNA) stock worth over $45 Million. Details can be seen in Mark N Lampert's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark N Lampert has not made any transactions after 2003-10-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark N Lampert
Mark N Lampert Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark N Lampert owns 48 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Royalty Corp (XOMA) among others .
Click here to see the complete history of Mark N Lampert’s form 4 insider trades.
Insider Ownership Summary of Mark N Lampert
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| FPRX | Five Prime Therapeutics Inc | 2020-10-06 | 10 percent owner |
| ELDN | Eledon Pharmaceuticals Inc | 2020-10-01 | 10 percent owner |
| XOMA | XOMA Royalty Corp | 2017-02-10 | 10 percent owner |
 | | 2020-01-01 | 10 percent owner |
| | 2021-06-16 | other: See Explanation of Responses |
| | 2020-08-18 | 10 percent owner |
| | 2020-06-18 | 10 percent owner |
| | 2019-06-19 | 10 percent owner |
| | 2017-06-09 | 10 percent owner |
| | 2019-12-09 | 10 percent owner |
| | 2018-11-16 | 10 percent owner |
| | 2017-05-01 | 10 percent owner |
| | 2017-09-19 | 10 percent owner |
| | 2016-11-30 | 10 percent owner |
| | 2018-12-04 | 10 percent owner |
| | 2017-11-28 | 10 percent owner |
| | 2018-05-30 | 10 percent owner |
| | 2016-09-08 | 10 percent owner |
| | 2017-11-17 | 10 percent owner |
| | 2014-07-01 | 10 percent owner |
| | 2017-05-08 | 10 percent owner |
| | 2016-06-23 | director & 10 percent owner |
| | 2012-08-28 | 10 percent owner |
| | 2009-07-09 | 10 percent owner |
| | 2009-08-24 | 10 percent owner & other: Indirect Beneficial Owner |
| | 2014-03-21 | other: See Explanation of Responses |
| | 2011-10-05 | 10 percent owner |
| | 2013-05-01 | 10 percent owner |
| | 2011-10-07 | 10 percent owner |
| | 2009-12-22 | 10 percent owner |
| | 2009-12-18 | 10 percent owner |
| | 2009-10-21 | 10 percent owner |
| | 2009-07-30 | 10 percent owner |
| | 2009-05-15 | 10 percent owner & other: Group Member |
| | 2003-10-17 | director & 10 percent owner |
| | 2017-02-10 | 10 percent owner |
| | 2020-12-18 | 10 percent owner |
| | 2022-01-25 | 10 percent owner |
| | 2021-04-22 | other: See Explanation of Responses |
| | 2020-11-18 | 10 percent owner |
| | 2021-12-31 | 10 percent owner |
| | 2021-10-28 | 10 percent owner |
| | 2022-04-05 | director & 10 percent owner |
| | 2022-06-16 | 10 percent owner |
| | 2022-07-11 | 10 percent owner |
| | 2022-12-19 | 10 percent owner |
| | 2023-02-03 | 10 percent owner |
| | 2023-11-02 | 10 percent owner |
Mark N Lampert Latest Holdings Summary
Mark N Lampert currently owns a total of 1 stock. Mark N Lampert owns 452,021 shares of Arena Pharmaceuticals Inc (ARNA) as of October 17, 2003, with a value of $45 Million.
Latest Holdings of Mark N Lampert
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ARNA | Arena Pharmaceuticals Inc | 2003-10-17 | 452,021 | 99.99 | 45,197,580 |
Holding Weightings of Mark N Lampert
Mark N Lampert Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark N Lampert has made a total of 0 transactions in Arena Pharmaceuticals Inc (ARNA) over the past 5 years. The most-recent trade in Arena Pharmaceuticals Inc is the sale of 291,100 shares on October 17, 2003, which brought Mark N Lampert around $22 Million.
Insider Trading History of Mark N Lampert
- 1
Mark N Lampert Trading Performance
Mark N Lampert Ownership Network
Ownership Network List of Mark N Lampert
Ownership Network Relation of Mark N Lampert
Mark N Lampert Owned Company Details
What does Five Prime Therapeutics Inc do?
Who are the key executives at Five Prime Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Inc/il .
Five Prime Therapeutics Inc (FPRX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Five Prime Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Eledon Pharmaceuticals Inc do?
Who are the key executives at Eledon Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .
Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Eledon Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does XOMA Royalty Corp do?
Who are the key executives at XOMA Royalty Corp?
Mark N Lampert is the 10 percent owner of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , Chief Financial Officer Thomas M. Burns , and other: See Explanation of Responses Biotechnology Value Fund L P .
XOMA Royalty Corp (XOMA) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in XOMA Royalty Corp (XOMA). Other recent insider transactions involving XOMA Royalty Corp (XOMA) include a net purchase of 7,284 shares made by Bradley Sitko , a net sale of 8,775 shares made by Thomas M. Burns , and a net sale of 650,717 shares made by Biotechnology Value Fund L P .
In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMA) in total and bought 28,134 shares, with a net purchase of 28,134 shares. During the past 18 months, 682,373 shares of XOMA Royalty Corp (XOMA) were sold and 28,284 shares were bought by its insiders, resulting in a net sale of 654,089 shares.
XOMA Royalty Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.
XOMA Royalty Corp Insider Transactions
- Download to Excel(.xls)
What does Merus NV do?
Who are the key executives at Merus NV?
Mark N Lampert is the 10 percent owner of Merus NV. Other key executives at Merus NV include Chief Accounting Officer Harry Shuman , EVP & General Counsel Peter B. Silverman , and director & President & CEO & PFO Sven Ante Lundberg .
Merus NV (MRUS) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Merus NV (MRUS). Other recent insider transactions involving Merus NV (MRUS) include a net sale of 24,240 shares made by Harry Shuman , and a net sale of 94,386 shares made by Peter B. Silverman .
In summary, during the past 3 months, insiders sold 4,000 shares of Merus NV (MRUS) in total and bought 0 shares, with a net sale of 4,000 shares. During the past 18 months, 118,626 shares of Merus NV (MRUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 118,626 shares.
Merus NV (MRUS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Merus NV Insider Transactions
- Download to Excel(.xls)
What does Kymera Therapeutics Inc do?
Who are the key executives at Kymera Therapeutics Inc?
Mark N Lampert is the other: See Explanation of Responses of Kymera Therapeutics Inc. Other key executives at Kymera Therapeutics Inc include Chief Legal Officer Ellen Chiniara , Chief Medical Officer Jared Gollob , and Chief Financial Officer Bruce N. Jacobs .
Kymera Therapeutics Inc (KYMR) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Kymera Therapeutics Inc (KYMR). Other recent insider transactions involving Kymera Therapeutics Inc (KYMR) include a net sale of 95,221 shares made by Jared Gollob , a net sale of 961,800 shares made by Bruce Booth , and a net sale of 20,000 shares made by Jeffrey W. Albers .
In summary, during the past 3 months, insiders sold 16,399 shares of Kymera Therapeutics Inc (KYMR) in total and bought 0 shares, with a net sale of 16,399 shares. During the past 18 months, 1,478,470 shares of Kymera Therapeutics Inc (KYMR) were sold and 414,106 shares were bought by its insiders, resulting in a net sale of 1,064,364 shares.
Kymera Therapeutics Inc (KYMR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Kymera Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Principia Biopharma Inc do?
Who are the key executives at Principia Biopharma Inc?
Mark N Lampert is the 10 percent owner of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include director & President & CEO Martin Babler , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .
Principia Biopharma Inc (PRNB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Principia Biopharma Inc Insider Transactions
- Download to Excel(.xls)
What does IDEAYA Biosciences Inc do?
Who are the key executives at IDEAYA Biosciences Inc?
Mark N Lampert is the 10 percent owner of IDEAYA Biosciences Inc. Other key executives at IDEAYA Biosciences Inc include SVP & Chief Scientific Officer Michael Anthony White , director & President and CEO Yujiro S Hata , and See Remarks Briseno Andres Ruiz .
IDEAYA Biosciences Inc (IDYA) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in IDEAYA Biosciences Inc (IDYA). Other recent insider transactions involving IDEAYA Biosciences Inc (IDYA) include a net sale of 425,000 shares made by Yujiro S Hata , a net sale of 8,000 shares made by Briseno Andres Ruiz , and a net sale of 15,163 shares made by Jason Throne .
In summary, during the past 3 months, insiders sold 0 shares of IDEAYA Biosciences Inc (IDYA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 476,663 shares of IDEAYA Biosciences Inc (IDYA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 476,663 shares.
IDEAYA Biosciences Inc (IDYA)'s detailed insider trading history can be found in Insider Trading Tracker table.
IDEAYA Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Calithera Biosciences Inc do?
Who are the key executives at Calithera Biosciences Inc?
Mark N Lampert is the 10 percent owner of Calithera Biosciences Inc. Other key executives at Calithera Biosciences Inc include director & 10 percent owner Deepika Pakianathan , 10 percent owner Takeda Ventures, Inc. , and SR. VP & CLINICAL DEVELOPMENT Keith Orford .
Calithera Biosciences Inc (CALA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Calithera Biosciences Inc (CALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Calithera Biosciences Inc (CALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Calithera Biosciences Inc (CALA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Calithera Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does CTI BioPharma Corp do?
Who are the key executives at CTI BioPharma Corp?
Mark N Lampert is the 10 percent owner of CTI BioPharma Corp. Other key executives at CTI BioPharma Corp include EVP & Chief Commercial Officer James K Fong , director & President and CEO Adam R Craig , and EVP & Chief Financial Officer David Kirske .
CTI BioPharma Corp (CTIC) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of CTI BioPharma Corp (CTIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CTI BioPharma Corp (CTIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
CTI BioPharma Corp (CTIC)'s detailed insider trading history can be found in Insider Trading Tracker table.
CTI BioPharma Corp Insider Transactions
- Download to Excel(.xls)
What does Cytokinetics Inc do?
Who are the key executives at Cytokinetics Inc?
Mark N Lampert is the 10 percent owner of Cytokinetics Inc. Other key executives at Cytokinetics Inc include SVP Research & Early Dev Fady Ibraham Malik , EVP & Corp. Development & CBO Robert I Blum , and EVP & Chief Commercial Officers Andrew Callos .
Cytokinetics Inc (CYTK) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Cytokinetics Inc (CYTK). Other recent insider transactions involving Cytokinetics Inc (CYTK) include a net sale of 231,815 shares made by Fady Ibraham Malik , a net sale of 321,861 shares made by Robert I Blum , and a net sale of 40,000 shares made by B Lynne Parshall .
In summary, during the past 3 months, insiders sold 216,954 shares of Cytokinetics Inc (CYTK) in total and bought 0 shares, with a net sale of 216,954 shares. During the past 18 months, 732,783 shares of Cytokinetics Inc (CYTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 732,783 shares.
Cytokinetics Inc (CYTK)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cytokinetics Inc Insider Transactions
- Download to Excel(.xls)
What does Pieris Pharmaceuticals Inc do?
Who are the key executives at Pieris Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Pieris Pharmaceuticals Inc. Other key executives at Pieris Pharmaceuticals Inc include 10 percent owner Bvf Gp Holdings Llc , 10 percent owner Bvf I Gp Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .
Pieris Pharmaceuticals Inc (PIRS) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Pieris Pharmaceuticals Inc (PIRS). Other recent insider transactions involving Pieris Pharmaceuticals Inc (PIRS) include a net purchase of 6,000 shares made by ,
In summary, during the past 3 months, insiders sold 0 shares of Pieris Pharmaceuticals Inc (PIRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pieris Pharmaceuticals Inc (PIRS) were sold and 6,000 shares were bought by its insiders, resulting in a net purchase of 6,000 shares.
Pieris Pharmaceuticals Inc (PIRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Pieris Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does GlycoMimetics Inc do?
Who are the key executives at GlycoMimetics Inc?
Mark N Lampert is the 10 percent owner of GlycoMimetics Inc. Other key executives at GlycoMimetics Inc include 10 percent owner Invus Public Equities, L.p. , Chief Medical Officer Edwin Rock , and CFO Brian M. Hahn .
GlycoMimetics Inc (GLYC) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in GlycoMimetics Inc (GLYC). Other recent insider transactions involving GlycoMimetics Inc (GLYC) include a net sale of 2,271,499 shares made by Invus Public Equities, L.p. , a net purchase of 305,000 shares made by Edwin Rock , and a net purchase of 17,500 shares made by Brian M. Hahn .
In summary, during the past 3 months, insiders sold 0 shares of GlycoMimetics Inc (GLYC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,271,499 shares of GlycoMimetics Inc (GLYC) were sold and 322,500 shares were bought by its insiders, resulting in a net sale of 1,948,999 shares.
GlycoMimetics Inc (GLYC)'s detailed insider trading history can be found in Insider Trading Tracker table.
GlycoMimetics Inc Insider Transactions
- Download to Excel(.xls)
What does Concert Pharmaceuticals Inc do?
Who are the key executives at Concert Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .
Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Concert Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Infinity Pharmaceuticals Inc do?
Who are the key executives at Infinity Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Infinity Pharmaceuticals Inc. Other key executives at Infinity Pharmaceuticals Inc include director & President & CEO Adelene Q Perkins , Chief Scientific Officer Stephane Peluso , and Chief Medical Officer Robert Jr. Ilaria .
Infinity Pharmaceuticals Inc (INFIQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Infinity Pharmaceuticals Inc (INFIQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Infinity Pharmaceuticals Inc (INFIQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Infinity Pharmaceuticals Inc (INFIQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Infinity Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Immune Design Corp do?
Who are the key executives at Immune Design Corp?
Mark N Lampert is the 10 percent owner of Immune Design Corp. Other key executives at Immune Design Corp include 10 percent owner & other: General Partner Column Group Gp, Lp , 10 percent owner Column Group L P , and 10 percent owner & other: General Partner Ponoi Management, Llc .
Immune Design Corp (IMDZ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Immune Design Corp (IMDZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immune Design Corp (IMDZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Immune Design Corp (IMDZ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Immune Design Corp Insider Transactions
- Download to Excel(.xls)
What does Syndax Pharmaceuticals Inc do?
Who are the key executives at Syndax Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include President and COO Michael A Metzger , President & Head of R&D Neil Gallagher , and Chief Financial Officer Keith A. Goldan .
Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 21,102 shares made by Michael A Metzger , a net sale of 2,527 shares made by Keith A. Goldan , and a net sale of 4,618 shares made by Neil Gallagher .
In summary, during the past 3 months, insiders sold 29,497 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 29,497 shares. During the past 18 months, 29,497 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 1,250 shares were bought by its insiders, resulting in a net sale of 28,247 shares.
Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Syndax Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Arqule Inc do?
Who are the key executives at Arqule Inc?
Mark N Lampert is the 10 percent owner of Arqule Inc. Other key executives at Arqule Inc include director & Chief Executive Officer Paolo Pucci , CFO and Treasurer Marc Schegerin , and See Remarks Brian Schwartz .
Arqule Inc (ARQL) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arqule Inc (ARQL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arqule Inc (ARQL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arqule Inc (ARQL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arqule Inc Insider Transactions
- Download to Excel(.xls)
What does Xenon Pharmaceuticals Inc do?
Who are the key executives at Xenon Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Xenon Pharmaceuticals Inc. Other key executives at Xenon Pharmaceuticals Inc include director & PRESIDENT & CEO Ian Mortimer , Chief Financial Officer Sherry Aulin , and SVP Bus. & Corp. Development Sherrington Robin .
Xenon Pharmaceuticals Inc (XENE) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Xenon Pharmaceuticals Inc (XENE). Other recent insider transactions involving Xenon Pharmaceuticals Inc (XENE) include a net sale of 31,467 shares made by Gary Patou , a net sale of 55,000 shares made by Ian Mortimer , and a net sale of 18,709 shares made by Sherry Aulin .
In summary, during the past 3 months, insiders sold 0 shares of Xenon Pharmaceuticals Inc (XENE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 127,405 shares of Xenon Pharmaceuticals Inc (XENE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 127,405 shares.
Xenon Pharmaceuticals Inc (XENE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xenon Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Regulus Therapeutics Inc do?
Who are the key executives at Regulus Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Operating Officer Joseph P Hagan , Sr. VP & General Counsel Christopher Ray Aker , and Chief Financial Officer Crispina Calsada .
Regulus Therapeutics Inc (RGLS) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 91,634 shares made by Joseph P Hagan , a net sale of 49,272 shares made by Crispina Calsada , and a net sale of 49,103 shares made by Christopher Ray Aker .
In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 69,610 shares, with a net purchase of 69,610 shares. During the past 18 months, 271,454 shares of Regulus Therapeutics Inc (RGLS) were sold and 73,610 shares were bought by its insiders, resulting in a net sale of 197,844 shares.
Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regulus Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Capstone Holding Corp do?
Who are the key executives at Capstone Holding Corp?
Mark N Lampert is the 10 percent owner of Capstone Holding Corp. Other key executives at Capstone Holding Corp include other: See Remarks Alimco Financial Corp , 10 percent owner Neil S Subin , and 10 percent owner Miller Lloyd I Iii .
Capstone Holding Corp (CAPS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Capstone Holding Corp (CAPS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Capstone Holding Corp (CAPS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Capstone Holding Corp (CAPS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Capstone Holding Corp Insider Transactions
- Download to Excel(.xls)
What does Alpine Immune Sciences Inc do?
Who are the key executives at Alpine Immune Sciences Inc?
Mark N Lampert is the 10 percent owner of Alpine Immune Sciences Inc. Other key executives at Alpine Immune Sciences Inc include Senior VP and CFO James Paul Rickey , director & Executive Chairman and CEO Mitchell Gold , and director & 10 percent owner Xiangmin Cui .
Alpine Immune Sciences Inc (ALPN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Alpine Immune Sciences Inc (ALPN). Other recent insider transactions involving Alpine Immune Sciences Inc (ALPN) include a net sale of 281,514 shares made by James Paul Rickey , a net sale of 213,302 shares made by Mitchell Gold , and a net sale of 1,546,347 shares made by Peter A. Thompson .
In summary, during the past 3 months, insiders sold 0 shares of Alpine Immune Sciences Inc (ALPN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,587,529 shares of Alpine Immune Sciences Inc (ALPN) were sold and 750,000 shares were bought by its insiders, resulting in a net sale of 2,837,529 shares.
Alpine Immune Sciences Inc (ALPN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Alpine Immune Sciences Inc Insider Transactions
- Download to Excel(.xls)
What does Cascadian Therapeutics Inc do?
Who are the key executives at Cascadian Therapeutics Inc?
Mark N Lampert is the director & 10 percent owner of Cascadian Therapeutics Inc. Other key executives at Cascadian Therapeutics Inc include 10 percent owner Nea Partners 15, L.p. , 10 percent owner New Enterprise Associates 15, L.p. , and 10 percent owner Jon Sakoda .
Cascadian Therapeutics Inc (CASC) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Cascadian Therapeutics Inc (CASC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cascadian Therapeutics Inc (CASC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Cascadian Therapeutics Inc (CASC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cascadian Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does ChemoCentryx Inc do?
Who are the key executives at ChemoCentryx Inc?
Mark N Lampert is the 10 percent owner of ChemoCentryx Inc. Other key executives at ChemoCentryx Inc include SVP Finance & CFO & Secretary Susan M Kanaya , director & 10 percent owner & President & CEO and Director Thomas J. Schall , and SVP & Finance & Acctg Officer Yi Ching Yau .
ChemoCentryx Inc (CCXI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ChemoCentryx Inc (CCXI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ChemoCentryx Inc (CCXI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ChemoCentryx Inc (CCXI)'s detailed insider trading history can be found in Insider Trading Tracker table.
ChemoCentryx Inc Insider Transactions
- Download to Excel(.xls)
What does Catalyst Biosciences Inc do?
Who are the key executives at Catalyst Biosciences Inc?
Mark N Lampert is the 10 percent owner of Catalyst Biosciences Inc. Other key executives at Catalyst Biosciences Inc include director & Chief Executive Officer Charles C Wu , director & President Songjiang Ma , and Chief Operating Officer Weiguo Ye .
Catalyst Biosciences Inc (CBIO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Catalyst Biosciences Inc (CBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Catalyst Biosciences Inc (CBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Catalyst Biosciences Inc (CBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Catalyst Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Ligand Pharmaceuticals Inc do?
Who are the key executives at Ligand Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner & other: Indirect Beneficial Owner of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include Chief Financial Officer Octavio Espinoza , CHIEF LEGAL OFFICER & Andrew Reardon , and VP & Finance and CFO Matthew E Korenberg .
Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 21,812 shares made by Octavio Espinoza , a net sale of 70,748 shares made by Matthew E Korenberg , and a net sale of 13,500 shares made by Andrew Reardon .
In summary, during the past 3 months, insiders sold 5,000 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 5,000 shares. During the past 18 months, 111,293 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 2,500 shares were bought by its insiders, resulting in a net sale of 108,793 shares.
Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ligand Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Regado Biosciences Inc do?
Who are the key executives at Regado Biosciences Inc?
Mark N Lampert is the other: See Explanation of Responses of Regado Biosciences Inc. Other key executives at Regado Biosciences Inc include 10 percent owner Associates Domain , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Christopher Peetz .
Regado Biosciences Inc (RGDO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Regado Biosciences Inc (RGDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regado Biosciences Inc (RGDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Regado Biosciences Inc (RGDO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regado Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Palatin Technologies Inc do?
Who are the key executives at Palatin Technologies Inc?
Mark N Lampert is the 10 percent owner of Palatin Technologies Inc. Other key executives at Palatin Technologies Inc include Executive Vice President & CFO Stephen T Wills , director & President and CEO Carl Spana , and director & Exec. VP Research and Devel. Perry B Molinoff .
Palatin Technologies Inc (PTN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Palatin Technologies Inc (PTN). Other recent insider transactions involving Palatin Technologies Inc (PTN) include a net sale of 9,997 shares made by Stephen T Wills , a net sale of 5,700 shares made by Deveer Robert K Jr , and a net sale of 200 shares made by Alan W Dunton .
In summary, during the past 3 months, insiders sold 0 shares of Palatin Technologies Inc (PTN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 21,897 shares of Palatin Technologies Inc (PTN) were sold and 6,000 shares were bought by its insiders, resulting in a net sale of 15,897 shares.
Palatin Technologies Inc (PTN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Palatin Technologies Inc Insider Transactions
- Download to Excel(.xls)
What does Rigel Pharmaceuticals Inc do?
Who are the key executives at Rigel Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & GC & Corp Sec Raymond J. Furey .
Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 62,246 shares made by Raul R Rodriguez , a net sale of 18,440 shares made by David A Santos , and a net sale of 16,398 shares made by Dean L Schorno .
In summary, during the past 3 months, insiders sold 19,830 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 19,830 shares. During the past 18 months, 27,834 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 27,834 shares.
Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rigel Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Neurocrine Biosciences Inc do?
Who are the key executives at Neurocrine Biosciences Inc?
Mark N Lampert is the 10 percent owner of Neurocrine Biosciences Inc. Other key executives at Neurocrine Biosciences Inc include Chief Medical Officer Eiry Roberts , Chief Regulatory Officer Ingrid Delaet , and Chief Scientific Officer Jude Onyia .
Neurocrine Biosciences Inc (NBIX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Neurocrine Biosciences Inc (NBIX). Other recent insider transactions involving Neurocrine Biosciences Inc (NBIX) include a net sale of 33,548 shares made by Ingrid Delaet , a net sale of 60,394 shares made by Darin Lippoldt , and a net sale of 119,327 shares made by Eiry Roberts .
In summary, during the past 3 months, insiders sold 60,998 shares of Neurocrine Biosciences Inc (NBIX) in total and bought 0 shares, with a net sale of 60,998 shares. During the past 18 months, 1,224,203 shares of Neurocrine Biosciences Inc (NBIX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,224,203 shares.
Neurocrine Biosciences Inc (NBIX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Neurocrine Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does EPIRUS Biopharmaceuticals Inc do?
Who are the key executives at EPIRUS Biopharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .
EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
EPIRUS Biopharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does MediciNova Inc do?
Who are the key executives at MediciNova Inc?
Mark N Lampert is the 10 percent owner of MediciNova Inc. Other key executives at MediciNova Inc include Chief Financial Officer Jason J Kruger , Chief Financial Officer Douglas Paulin , and Chief Scientific Officer Gaeta Federico C.a. .
MediciNova Inc (MNOV) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of MediciNova Inc (MNOV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MediciNova Inc (MNOV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
MediciNova Inc (MNOV)'s detailed insider trading history can be found in Insider Trading Tracker table.
MediciNova Inc Insider Transactions
- Download to Excel(.xls)
What does Neurobiological Technologies Inc do?
Who are the key executives at Neurobiological Technologies Inc?
Mark N Lampert is the 10 percent owner of Neurobiological Technologies Inc. Other key executives at Neurobiological Technologies Inc include 10 percent owner Ariel Warszawski , 10 percent owner Ryan Heslop , and 10 percent owner Firefly Management Co Gp, Llc .
Neurobiological Technologies Inc (NTII) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Neurobiological Technologies Inc (NTII) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neurobiological Technologies Inc (NTII) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Neurobiological Technologies Inc (NTII)'s detailed insider trading history can be found in Insider Trading Tracker table.
Neurobiological Technologies Inc Insider Transactions
- Download to Excel(.xls)
What does Dynavax Technologies Corp do?
Who are the key executives at Dynavax Technologies Corp?
Mark N Lampert is the 10 percent owner of Dynavax Technologies Corp. Other key executives at Dynavax Technologies Corp include Senior Vice President David F Novack , Principal Accounting Officer Justin Burgess , and Chief Medical Officer and VP Robert Janssen .
Dynavax Technologies Corp (DVAX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Dynavax Technologies Corp (DVAX). Other recent insider transactions involving Dynavax Technologies Corp (DVAX) include a net sale of 125,784 shares made by David F Novack , a net sale of 20,526 shares made by Justin Burgess , and a net sale of 3,615 shares made by Francis Cano .
In summary, during the past 3 months, insiders sold 56,784 shares of Dynavax Technologies Corp (DVAX) in total and bought 0 shares, with a net sale of 56,784 shares. During the past 18 months, 151,425 shares of Dynavax Technologies Corp (DVAX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 151,425 shares.
Dynavax Technologies Corp (DVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Dynavax Technologies Corp Insider Transactions
- Download to Excel(.xls)
What does Repligen Corp do?
Who are the key executives at Repligen Corp?
Mark N Lampert is the 10 percent owner & other: Group Member of Repligen Corp. Other key executives at Repligen Corp include director & Chief Executive Officer Anthony Hunt , Senior VP & R&D Ralf Kuriyel , and SVP & Global Operations & IT James Bylund .
Repligen Corp (RGEN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Repligen Corp (RGEN). Other recent insider transactions involving Repligen Corp (RGEN) include a net sale of 107,972 shares made by Anthony Hunt , a net sale of 15,130 shares made by Ralf Kuriyel , and a net sale of 4,373 shares made by James Bylund .
In summary, during the past 3 months, insiders sold 26,756 shares of Repligen Corp (RGEN) in total and bought 250 shares, with a net sale of 26,506 shares. During the past 18 months, 134,263 shares of Repligen Corp (RGEN) were sold and 5,065 shares were bought by its insiders, resulting in a net sale of 129,198 shares.
Repligen Corp (RGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Repligen Corp Insider Transactions
- Download to Excel(.xls)
What does Arena Pharmaceuticals Inc do?
Who are the key executives at Arena Pharmaceuticals Inc?
Mark N Lampert is the director & 10 percent owner of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include director & President and CEO Amit Munshi , EVP & Chief Commercial Officer Robert Lisicki , and Executive VP and CBO Vincent Aurentz .
Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arena Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does XOMA Royalty Corp do?
Who are the key executives at XOMA Royalty Corp?
Mark N Lampert is the 10 percent owner of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and 10 percent owner Bvf Ii Gp Llc .
XOMA Royalty Corp (XOMAO.PFD) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
XOMA Royalty Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.
XOMA Royalty Corp Insider Transactions
- Download to Excel(.xls)
What does CytomX Therapeutics Inc do?
Who are the key executives at CytomX Therapeutics Inc?
Mark N Lampert is the 10 percent owner of CytomX Therapeutics Inc. Other key executives at CytomX Therapeutics Inc include SVP & Chief Scientific Officer Marcia Belvin , SVP & Finance and Accounting Christopher Ogden , and Chief Medical Officer Yu-waye Chu .
CytomX Therapeutics Inc (CTMX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in CytomX Therapeutics Inc (CTMX). Other recent insider transactions involving CytomX Therapeutics Inc (CTMX) include a net sale of 85,328 shares made by Sean A. Mccarthy , a net sale of 40,565 shares made by Marcia Belvin , and a net sale of 23,729 shares made by Lloyd A Rowland .
In summary, during the past 3 months, insiders sold 79,947 shares of CytomX Therapeutics Inc (CTMX) in total and bought 0 shares, with a net sale of 79,947 shares. During the past 18 months, 183,963 shares of CytomX Therapeutics Inc (CTMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 183,963 shares.
CytomX Therapeutics Inc (CTMX)'s detailed insider trading history can be found in Insider Trading Tracker table.
CytomX Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Verastem Inc do?
Who are the key executives at Verastem Inc?
Mark N Lampert is the 10 percent owner of Verastem Inc. Other key executives at Verastem Inc include Vice President of Finance Daniel Calkins , Chief Operating Officer Dan Paterson , and Chief Financial Officer Robert E. Gagnon .
Verastem Inc (VSTM) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 565 shares made by Daniel Calkins , a net sale of 15,864 shares made by Dan Paterson , and a net sale of 20,766 shares made by Robert E. Gagnon .
In summary, during the past 3 months, insiders sold 2,070 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 2,070 shares. During the past 18 months, 42,152 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 42,152 shares.
Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Verastem Inc Insider Transactions
- Download to Excel(.xls)
What does Rain Oncology Inc do?
Who are the key executives at Rain Oncology Inc?
Mark N Lampert is the other: See Explanation of Responses of Rain Oncology Inc. Other key executives at Rain Oncology Inc include 10 percent owner Kevin C Tang , Principal Fin. & Acc. Officer Josephine Bruce , and 10 percent owner Tang Capital Management Llc .
Rain Oncology Inc (RAIN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Rain Oncology Inc (RAIN). Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net sale of 173,973 shares made by Kevin C Tang ,
In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 173,973 shares of Rain Oncology Inc (RAIN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 173,973 shares.
Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rain Oncology Inc Insider Transactions
- Download to Excel(.xls)
What does Olema Pharmaceuticals inc do?
Who are the key executives at Olema Pharmaceuticals inc?
Mark N Lampert is the 10 percent owner of Olema Pharmaceuticals inc. Other key executives at Olema Pharmaceuticals inc include director & Chief Technology Officer Cyrus Harmon , director & President and CEO Sean Bohen , and Chief Development Officer David C. Myles .
Olema Pharmaceuticals inc (OLMA) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Olema Pharmaceuticals inc (OLMA). Other recent insider transactions involving Olema Pharmaceuticals inc (OLMA) include a net sale of 254,574 shares made by Cyrus Harmon , a net sale of 2,410,761 shares made by G. Walmsley Graham , and a net sale of 50,436 shares made by David C. Myles .
In summary, during the past 3 months, insiders sold 0 shares of Olema Pharmaceuticals inc (OLMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,719,521 shares of Olema Pharmaceuticals inc (OLMA) were sold and 1,740,761 shares were bought by its insiders, resulting in a net sale of 4,978,760 shares.
Olema Pharmaceuticals inc (OLMA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Olema Pharmaceuticals inc Insider Transactions
- Download to Excel(.xls)
What does Cullinan Therapeutics Inc do?
Who are the key executives at Cullinan Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Cullinan Therapeutics Inc. Other key executives at Cullinan Therapeutics Inc include director & President and CEO Nadim Ahmed , Chief Legal Officer Jacquelyn L Sumer , and Chief Medical Officer Jeffrey Alan Jones .
Cullinan Therapeutics Inc (CGEM) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Cullinan Therapeutics Inc (CGEM). Other recent insider transactions involving Cullinan Therapeutics Inc (CGEM) include a net sale of 105,995 shares made by Jennifer Michaelson , a net sale of 11,773 shares made by Jeffrey Alan Jones , and a net sale of 8,928 shares made by Jacquelyn L Sumer .
In summary, during the past 3 months, insiders sold 24,936 shares of Cullinan Therapeutics Inc (CGEM) in total and bought 0 shares, with a net sale of 24,936 shares. During the past 18 months, 276,141 shares of Cullinan Therapeutics Inc (CGEM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 276,141 shares.
Cullinan Therapeutics Inc (CGEM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cullinan Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Repare Therapeutics Inc do?
Who are the key executives at Repare Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Repare Therapeutics Inc. Other key executives at Repare Therapeutics Inc include EVP & Chief Medical Officer Maria Koehler , EVP & Chief Science Officer Michael Zinda , and EVP & Chief Financial Officer Steve Forte .
Repare Therapeutics Inc (RPTX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Repare Therapeutics Inc (RPTX). Other recent insider transactions involving Repare Therapeutics Inc (RPTX) include a net sale of 34,270 shares made by Lloyd Mitchell Segal , a net sale of 10,973 shares made by Steve Forte , and a net sale of 7,821 shares made by Michael Zinda .
In summary, during the past 3 months, insiders sold 37,270 shares of Repare Therapeutics Inc (RPTX) in total and bought 0 shares, with a net sale of 37,270 shares. During the past 18 months, 58,960 shares of Repare Therapeutics Inc (RPTX) were sold and 2,011,010 shares were bought by its insiders, resulting in a net purchase of 1,952,050 shares.
Repare Therapeutics Inc (RPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Repare Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does MoonLake Immunotherapeutics do?
Who are the key executives at MoonLake Immunotherapeutics?
Mark N Lampert is the director & 10 percent owner of MoonLake Immunotherapeutics. Other key executives at MoonLake Immunotherapeutics include director & 10 percent owner Biotechnology Value Fund L P , director & Chief Executive Officer Santos Da Silva Jorge , and Chief Scientific Officer Kristian Reich .
MoonLake Immunotherapeutics (MLTX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in MoonLake Immunotherapeutics (MLTX). Other recent insider transactions involving MoonLake Immunotherapeutics (MLTX) include a net sale of 200,000 shares made by Kristian Reich , a net sale of 184,740 shares made by Santos Da Silva Jorge , and a net sale of 2,000,000 shares made by Biotechnology Value Fund L P .
In summary, during the past 3 months, insiders sold 0 shares of MoonLake Immunotherapeutics (MLTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,655,740 shares of MoonLake Immunotherapeutics (MLTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,655,740 shares.
MoonLake Immunotherapeutics (MLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
MoonLake Immunotherapeutics Insider Transactions
- Download to Excel(.xls)
What does 4D Molecular Therapeutics Inc do?
Who are the key executives at 4D Molecular Therapeutics Inc?
Mark N Lampert is the 10 percent owner of 4D Molecular Therapeutics Inc. Other key executives at 4D Molecular Therapeutics Inc include Chief Legal and HR Officer Scott Bizily , director & Chief Executive Officer David Kirn , and Chief Medical Officer Robert Young Kim .
4D Molecular Therapeutics Inc (FDMT) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in 4D Molecular Therapeutics Inc (FDMT). Other recent insider transactions involving 4D Molecular Therapeutics Inc (FDMT) include a net sale of 39,883 shares made by Scott Bizily , a net sale of 225,853 shares made by David Kirn , and a net sale of 540,000 shares made by Viking Global Investors Lp .
In summary, during the past 3 months, insiders sold 0 shares of 4D Molecular Therapeutics Inc (FDMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 830,288 shares of 4D Molecular Therapeutics Inc (FDMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 830,288 shares.
4D Molecular Therapeutics Inc (FDMT)'s detailed insider trading history can be found in Insider Trading Tracker table.
4D Molecular Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does ESSA Pharma Inc do?
Who are the key executives at ESSA Pharma Inc?
Mark N Lampert is the 10 percent owner of ESSA Pharma Inc. Other key executives at ESSA Pharma Inc include 10 percent owner Biotech Growth N V , Chief Operating Officer Peter Virsik , and director & Chief Executive Officer David Ross Parkinson .
ESSA Pharma Inc (EPIX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in ESSA Pharma Inc (EPIX). Other recent insider transactions involving ESSA Pharma Inc (EPIX) include a net sale of 81,945 shares made by Peter Virsik , a net purchase of 99,730 shares made by Franklin M Berger , and a net sale of 7,879,583 shares made by Biotech Growth N V .
In summary, during the past 3 months, insiders sold 0 shares of ESSA Pharma Inc (EPIX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,961,528 shares of ESSA Pharma Inc (EPIX) were sold and 108,953 shares were bought by its insiders, resulting in a net sale of 7,852,575 shares.
ESSA Pharma Inc (EPIX)'s detailed insider trading history can be found in Insider Trading Tracker table.
ESSA Pharma Inc Insider Transactions
- Download to Excel(.xls)
What does Third Harmonic Bio Inc do?
Who are the key executives at Third Harmonic Bio Inc?
Mark N Lampert is the 10 percent owner of Third Harmonic Bio Inc. Other key executives at Third Harmonic Bio Inc include Chief Medical Officer Edward R. Conner , other: See Explanation of Responses Biotechnology Value Fund L P , and Chief Administrative Officer Julie Person .
Third Harmonic Bio Inc (THRD) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Third Harmonic Bio Inc (THRD). Other recent insider transactions involving Third Harmonic Bio Inc (THRD) include a net sale of 33,970 shares made by Julie Person , a net sale of 14,370 shares made by Edward R. Conner , and a net sale of 25,114 shares made by .
In summary, during the past 3 months, insiders sold 0 shares of Third Harmonic Bio Inc (THRD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,107,234 shares of Third Harmonic Bio Inc (THRD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,107,234 shares.
Third Harmonic Bio Inc (THRD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Third Harmonic Bio Inc Insider Transactions
- Download to Excel(.xls)
What does Structure Therapeutics Inc do?
Who are the key executives at Structure Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Structure Therapeutics Inc. Other key executives at Structure Therapeutics Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Gp Holdings Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .
Structure Therapeutics Inc (GPCR) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Structure Therapeutics Inc (GPCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Structure Therapeutics Inc (GPCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Structure Therapeutics Inc (GPCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Structure Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does POINT Biopharma Global Inc do?
Who are the key executives at POINT Biopharma Global Inc?
Mark N Lampert is the 10 percent owner of POINT Biopharma Global Inc. Other key executives at POINT Biopharma Global Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Gp Holdings Llc .
POINT Biopharma Global Inc (PNT) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in POINT Biopharma Global Inc (PNT). Other recent insider transactions involving POINT Biopharma Global Inc (PNT) include a net sale of 17,161,278 shares made by Biotechnology Value Fund L P ,
In summary, during the past 3 months, insiders sold 0 shares of POINT Biopharma Global Inc (PNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,161,278 shares of POINT Biopharma Global Inc (PNT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 17,161,278 shares.
POINT Biopharma Global Inc (PNT)'s detailed insider trading history can be found in Insider Trading Tracker table.
POINT Biopharma Global Inc Insider Transactions
- Download to Excel(.xls)
Mark N Lampert Mailing Address
Above is the net worth, insider trading, and ownership report for Mark N Lampert. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Mark N Lampert's mailing address is: San Francisco Ca 94104.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
